Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCRTR1 | O43613 | 7/20 | 0.40 |
| ▸ | HCRTR2 | O43614 | 7/20 | 0.40 |
| ▸ | GRM5 | P41594 | 8/20 | 0.39 |
| ▸ | NTRK1 | P04629 | 2/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.37 |
| ▸ | KDM1A | O60341 | 1/20 | 0.36 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.35 |
| ▸ | NAMPT | P43490 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4931055 | 0.91 | GRM5 (0.42) | HCRTR1HCRTR2GRM5NTRK1NAMPT | |
| SCHEMBL4932667 | 0.84 | MGLL (0.46) | KDM1A | |
| SCHEMBL4927658 | 0.83 | VNN1 (0.42) | GRM5CYP3A4KDM1ACYP2A6 | |
| SCHEMBL14261654 | 0.82 | KDM1A (0.43) | GRM5CYP3A4KDM1ACYP2A6 | |
| SCHEMBL4932654 | 0.82 | PDK2 (0.40) | HCRTR1HCRTR2NTRK1KDM1ANAMPT | |
| SCHEMBL4925391 | 0.82 | KDM1A (0.44) | KDM1A | |
| SCHEMBL4932956 | 0.81 | GRM5 (0.36) | HCRTR1HCRTR2GRM5CYP3A4KDM1A | |
| SCHEMBL4927907 | 0.81 | KDM1A (0.46) | GRM5CYP3A4KDM1ACYP2A6 | |
| SCHEMBL4933965 | 0.79 | KDM1A (0.44) | NTRK1KDM1A | |
| SCHEMBL4927976 | 0.79 | CYP3A4 (0.39) | GRM5CYP3A4KDM1ACYP2A6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080064682-A1 | Pyrazole Derivatives | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2008-03-13 | — | — | US | disclosed |
| US-20080064682-A1 | Pyrazole Derivatives | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2008-03-13 | — | — | US | disclosed |
| US-20080064682-A1 | Pyrazole Derivatives | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2008-03-13 | — | — | US | disclosed |
| EP-1762568-A1 | PYRAZOLE DERIVATIVES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2007-03-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080064682-A1 | Pyrazole Derivatives | NAT1, AR, CBR3 | HCRTR1 1991/4885HCRTR2 1254/4885GRM5 1347/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.